Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.

Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Motzer RJ.

Ann Oncol. 2011 Feb;22(2):295-300. doi: 10.1093/annonc/mdq342. Epub 2010 Jul 25.

PMID:
20657034
[PubMed - indexed for MEDLINE]
Free Article
2.

Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.

Yuasa T, Tsuchiya N, Urakami S, Horikawa Y, Narita S, Inoue T, Saito M, Yamamoto S, Yonese J, Fukui I, Nakano K, Takahashi S, Hatake K, Habuchi T.

BJU Int. 2012 May;109(9):1349-54. doi: 10.1111/j.1464-410X.2011.10534.x. Epub 2011 Aug 25.

PMID:
21883864
[PubMed - indexed for MEDLINE]
3.

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma.

Motzer RJ, Escudier B, Bukowski R, Rini BI, Hutson TE, Barrios CH, Lin X, Fly K, Matczak E, Gore ME.

Br J Cancer. 2013 Jun 25;108(12):2470-7. doi: 10.1038/bjc.2013.236. Epub 2013 May 21.

PMID:
23695024
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.

Tsimafeyeu I, Zart JS, Chung B.

BJU Int. 2013 Jul;112(1):32-8. doi: 10.1111/bju.12107. Epub 2013 Jun 7.

PMID:
23746142
[PubMed - indexed for MEDLINE]
5.

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Bukowski RM, Figlin RA, Hutson TE, Michaelson MD, Kim ST, Baum CM, Kattan MW.

Cancer. 2008 Oct 1;113(7):1552-8. doi: 10.1002/cncr.23776.

PMID:
18720362
[PubMed - indexed for MEDLINE]
Free Article
6.

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.

Harmon CS, DePrimo SE, Figlin RA, Hudes GR, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Williams JA, Eisen T, Motzer RJ.

Cancer Chemother Pharmacol. 2014 Jan;73(1):151-61. doi: 10.1007/s00280-013-2333-4. Epub 2013 Nov 13.

PMID:
24220935
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha.

Dirican A, Kucukzeybek Y, Erten C, Somali I, Demir L, Can A, Payzin KB, Bayoglu IV, Akyol M, Yildiz Y, Koeseoglu M, Alacacioglu A, Tarhan MO.

Asian Pac J Cancer Prev. 2013;14(3):2101-5.

PMID:
23679326
[PubMed - indexed for MEDLINE]
Free Article
8.

Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.

Beuselinck B, Vano YA, Oudard S, Wolter P, De Smet R, Depoorter L, Teghom C, Karadimou A, Zucman-Rossi J, Debruyne PR, Van Poppel H, Joniau S, Lerut E, Strijbos M, Dumez H, Paridaens R, Van Calster B, Schöffski P.

BJU Int. 2014 Jul;114(1):81-9. doi: 10.1111/bju.12494. Epub 2014 Jan 15.

PMID:
24215209
[PubMed - indexed for MEDLINE]
9.

Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.

Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM.

Urol Oncol. 2013 Oct;31(7):1283-91. doi: 10.1016/j.urolonc.2011.08.010. Epub 2011 Sep 29.

PMID:
21956044
[PubMed - indexed for MEDLINE]
10.

Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.

Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E.

J Urol. 2014 Mar;191(3):611-8. doi: 10.1016/j.juro.2013.08.090. Epub 2013 Sep 7.

PMID:
24018239
[PubMed - indexed for MEDLINE]
11.

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.

Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antràs L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK.

Urol Oncol. 2011 Nov-Dec;29(6):756-63. doi: 10.1016/j.urolonc.2010.01.008. Epub 2010 May 6.

PMID:
20451414
[PubMed - indexed for MEDLINE]
12.

Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.

Beuselinck B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J, Elaidi R, Schöffski P, Barrascout E, Morel A, Escudier B, Lang H, Zucman-Rossi J, Medioni J.

Ann Oncol. 2011 Apr;22(4):794-800. doi: 10.1093/annonc/mdq554. Epub 2010 Oct 11.

PMID:
20937648
[PubMed - indexed for MEDLINE]
Free Article
13.

Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.

Seidel C, Busch J, Weikert S, Steffens S, Fenner M, Ganser A, Grünwald V.

Eur J Cancer. 2012 May;48(7):1023-30. doi: 10.1016/j.ejca.2012.02.048. Epub 2012 Mar 20.

PMID:
22436979
[PubMed - indexed for MEDLINE]
14.

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration.

Bamias A, Tzannis K, Beuselinck B, Oudard S, Escudier B, Diosynopoulos D, Papazisis K, Lang H, Wolter P, de Guillebon E, Stravodimos K, Chrisofos M, Fountzilas G, Elaidi RT, Dimopoulos MA, Bamia C.

Br J Cancer. 2013 Jul 23;109(2):332-41. doi: 10.1038/bjc.2013.341. Epub 2013 Jun 27.

PMID:
23807171
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.

Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O'Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A.

Eur Urol. 2011 Sep;60(3):448-54. doi: 10.1016/j.eururo.2011.05.028. Epub 2011 May 17.

PMID:
21612860
[PubMed - indexed for MEDLINE]
16.

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM.

Cancer. 2007 Aug 1;110(3):543-50.

PMID:
17577222
[PubMed - indexed for MEDLINE]
Free Article
17.

Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.

Bamias A, Karadimou A, Lampaki S, Lainakis G, Malettou L, Timotheadou E, Papazisis K, Andreadis C, Kontovinis L, Anastasiou I, Stravodimos K, Xanthakis I, Skolarikos A, Christodoulou C, Syrigos K, Papandreou C, Razi E, Dafni U, Fountzilas G, Dimopoulos MA.

BMC Cancer. 2010 Feb 18;10:45. doi: 10.1186/1471-2407-10-45.

PMID:
20163744
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.

Park SJ, Lee JL, Park I, Park K, Ahn Y, Ahn JH, Lee DH, Ahn S, Song C, Hong JH, Kim CS, Ahn H.

Chemotherapy. 2012;58(6):468-74. doi: 10.1159/000346484. Epub 2013 Mar 20.

PMID:
23548259
[PubMed - indexed for MEDLINE]
19.

Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib.

Terakawa T, Miyake H, Kusuda Y, Fujisawa M.

Urol Oncol. 2013 May;31(4):493-8. doi: 10.1016/j.urolonc.2011.02.012. Epub 2011 Apr 7.

PMID:
21478036
[PubMed - indexed for MEDLINE]
20.

Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.

Gigante M, Li G, Ferlay C, Perol D, Blanc E, Paul S, Zhao A, Tostain J, Escudier B, Negrier S, Genin C.

Anticancer Res. 2012 Dec;32(12):5447-51.

PMID:
23225450
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk